lifestyle.tvshowauditions.info

Author: Mylan Inc.

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

February 26, 2026
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

February 25, 2026
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

February 10, 2026
Viatris Appoints Matthew J. Maletta as Chief Legal Officer

February 10, 2026
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company’s First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

January 23, 2026
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

January 8, 2026
Viatris Provides Pipeline Update on Four Regulatory Milestones

December 20, 2025
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 19, 2025
Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back

December 15, 2025
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

December 7, 2025